NCT02938572View on ClinicalTrials.gov

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 19, 2016

Primary Completion Date

June 17, 2017

Study Completion Date

July 4, 2017

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

NNC0143-0406

Administered subcutaneously (s.c. under the skin)

DRUG

Insulin Aspart

Administered subcutaneously (s.c. under the skin)

Trial Locations (1)

8010

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02938572 - A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter